HPV and hepatitis B vaccination — prevention, not cancer treatment

They prevent virus infections, not tumours. The HPV vaccine is given before exposure to the high-risk human papillomavirus types behind almost all cervical cancer and some anal, vulvar, vaginal, penile and throat cancers. The hepatitis B vaccine prevents the long-term liver infection that drives much liver cancer. Both act years before any cancer appears.

Only a small number of cancers have a known infectious cause. HPV and hepatitis B are two of them, which is why vaccination can lower the risk of those particular cancers — and why no vaccine exists for the many cancers that have no single virus behind them.

• The HPV vaccine. It works against persistent infection with high-risk human papillomavirus types. Persistent infection with these types is linked to almost all cervical cancer, and to a proportion of anal, vulvar, vaginal, penile and oropharyngeal (throat) cancers.
• The hepatitis B vaccine. It prevents chronic hepatitis B infection. Chronic infection is a leading cause of liver inflammation, cirrhosis and liver cancer, usually over decades rather than months.
• Both are prophylactic. They are designed to be given before exposure, which is why they are scheduled in infancy and adolescence rather than at the point a symptom appears.
• Neither covers everything. The HPV vaccine does not cover every high-risk type, so cervical screening is still advised for vaccinated women on the schedule a doctor recommends. Hepatitis B vaccination does not protect against hepatitis C or against liver damage from alcohol or fatty liver disease.

Source: WHO and ICMR patient-education guidance on vaccine-preventable infections and cancer risk. This page gives no protection figures and no efficacy claims; ask your doctor what the current guidance says for your family.

No. Neither vaccine has any effect on an existing cancer. A preventive vaccine stops an infection before it takes hold, so once a cancer is present there is nothing left for it to prevent. It will not shrink a tumour, slow it down, or replace surgery, radiotherapy, chemotherapy or immunotherapy.

Three follow-on points matter, because this is where the confusion usually sits.

• The hepatitis B vaccine does nothing for someone already infected. A person with chronic hepatitis B needs liver assessment, monitoring and, in some cases, antiviral treatment and liver-cancer surveillance decided by a specialist. Their household contacts, however, should be tested and vaccinated — that part is genuinely useful and often forgotten.
• HPV vaccination after a diagnosis is not treatment. If cervical or another HPV-linked cancer has already been diagnosed, treatment decisions are made on the biopsy, the stage and the scans. Vaccination is a separate conversation about the rest of the family.
• Some vaccines are advised during cancer treatment — for infection, not for cancer. Oncology teams do recommend certain non-live vaccinations to patients on treatment to protect them from infection. Timing matters and some vaccines are avoided while the immune system is suppressed, so never take one during treatment without asking the treating team first.

No, though both involve the immune system. A preventive vaccine trains a healthy immune system against a virus, years before any cancer could form. Cancer immunotherapy is a prescription treatment given to a person who already has cancer. Different people, different purpose, different setting: one is public health, the other is oncology.

Cell therapies are a fifth category again. Some are approved in India for certain blood cancers and are delivered only at a small number of accredited centres. CION does not provide, administer or stock CAR-T or any cell therapy, and refers patients to licensed centres when it is relevant. Anything sold as a “cell therapy package” outside that route should be checked with an oncologist first.

WHO guidance puts the main benefit in girls aged 9 to 14, before likely exposure to the virus. Older adolescents and young adults may still be advised to have it, and boys are vaccinated in several countries and privately in India. The number of doses depends on age at first dose and on immune status.

1. 1

   Girls aged 9 to 14 — the main group

   Vaccination is aimed at this age band because it works best when given before exposure to the virus, not because anything is assumed about the child. WHO now supports fewer doses in this age group than for older recipients.

2. 2

   Older adolescents and young adults

   Catch-up vaccination is often still advised, with a doctor deciding the schedule. The benefit is generally smaller with increasing age and possible prior exposure, which is a reason to ask rather than a reason to skip the conversation.

3. 3

   Boys

   HPV also causes anal, penile and throat cancers, and gender-neutral vaccination is recommended by WHO where feasible. In India it is available for boys through private clinics; ask a paediatrician what applies in your state.

4. 4

   Screening does not stop

   Vaccination does not replace cervical screening, because the vaccine does not cover every high-risk type. Women should continue screening on the schedule their doctor recommends, whether or not they were vaccinated.

Availability in India. India has an HPV vaccine manufactured domestically and licensed by CDSCO, alongside imported options, and government provision for adolescent girls has been expanding but still differs by state and by year. Where it is provided through a government programme it is free; privately the cost varies with the vaccine type and the number of doses, so ask the clinic for a written figure before you commit (indicative, as of August 2026). Your paediatrician or district immunisation office can confirm what is currently offered in Telangana or Andhra Pradesh.

Every infant, under the Universal Immunisation Programme, starting with a birth dose. Adults who were never vaccinated can still have it, and it is particularly recommended for household and sexual contacts of an infected person, healthcare workers, people on dialysis and people with chronic liver disease.

• Infants. A birth dose followed by further doses alongside the routine infant schedule. This is the single most effective place to interrupt the chain, because infection acquired in infancy is the most likely to become chronic.
• Unvaccinated adults. Vaccination is still possible at any age. Adults are often tested first, because the vaccine protects people who are not yet infected and does nothing for someone who already carries the virus.
• Household and close contacts. If one person in a family is found to have chronic hepatitis B, the rest of the household should be tested and vaccinated where appropriate. This is frequently the step that gets missed.
• Anyone who tests positive. They need liver assessment, monitoring and a specialist opinion, not a vaccine. Liver-cancer surveillance may be advised, and that decision belongs to a hepatologist or oncologist.

Source: national immunisation schedule and WHO hepatitis B guidance, patient-education context. Testing and dosing decisions for adults belong to a treating doctor.

Separate the two jobs. For the patient, the useful steps are a confirmed diagnosis, the tests their oncologist asks for, and a written treatment plan. For everyone else in the family, vaccination and screening are real prevention. Doing the second is worthwhile. Doing it instead of the first is where harm happens.

Nobody arrives at an immunity drip or a vaccine-for-cancer offer because they are careless. They arrive there because someone offered certainty at a moment when the hospital was offering caution, and because the word “immunity” is used to mean four different things in the same conversation.

• Ask what the actual next step is. Biopsy confirmation, staging scans, and whether any biomarker testing is relevant. These decide what treatment is even possible.
• Ask directly whether immunotherapy applies. It is a real treatment for a minority of patients, decided on cancer type, stage and biomarker results. An oncologist can tell you in one appointment whether it is relevant here.
• Vaccinate the healthy people in the family. Children and adolescents for HPV, unvaccinated adults and household contacts for hepatitis B. This is the prevention that is genuinely within your control today.
• Tell the oncology team about anything already taken. Injections, drips, herbal preparations or supplements. Some affect blood counts, liver or kidney function, and hiding them is the only part of this that adds risk.

CION oncologists have this conversation constantly and without judgement. Nothing you disclose changes whether a patient is treated, or how.

• Dendritic Cell Therapy: Evidence and Availability in India — often described to families as a “cancer vaccine”, so it is worth reading what the evidence and the availability actually are.
• NK Cell Therapy and Other Cell Treatments Offered Privately — the cell-therapy category explained, including which parts are approved in India and which are being sold outside that route.
• Ozone, Hyperthermia and “Immune” Therapies Sold to Cancer Patients — the wider set of practices marketed on the word “immunity”, and how to check any of them before paying.
• Immunotherapy at CION Cancer Clinics — what genuine immunotherapy is, how it is assessed and delivered as day care here, and who is and is not a candidate for it.

This page is general information about vaccination and cancer prevention and does not replace a consultation. It names no vaccine brands or drug molecules and makes no efficacy claims. Vaccination decisions, including timing during cancer treatment, must be taken with your doctor or your treating oncology team.

Families ask us this every week

Vaccine, immunity booster, immunotherapy — the words get mixed up constantly, and there is no shame in asking which is which. We will explain it in plain language, at no cost.